Posted by Michael Wonder on 13 Apr 2020
Astellas announces acceptance of Xospata (gilteritinib) for regulatory review in China by the National Medical Products Administration
10 April 2020 - Astellas announced today a new drug application for the oral once-daily therapy Xospata (gilteritinib), for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia with a FLT3 mutation has been accepted by the National Medical Products Administration for regulatory review in China.
